



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,
VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA.
TEL : 0260-2430027
Email : hrm@gtbl.in.net
CIN No.: L24230GJ1981PLC004878

GTBL: CS: BSE-CORR/2022-23

27th July, 2022

BSE Limited,
P. J. Towers, Dalal Street,
Mumbai-400001

Dear Sir/Madam,

Sub: Corrigendum to the disclosure under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 dated July 27, 2022 w.r.t filing of Unaudited Financial Results of the Company for the quarter ended June 30, 2022.

This has reference to the Unaudited Financial results for the quarter ended June 30, 2022 of our Company as approved by the Board of Directors and uploaded on website on July 27, 2022.

Under the Serial No. IV Total expenses should be read as ₹ 2,279.80 Lakhs instead of ₹ 2,279.78 Lakhs and the consequential changes of the same is reflected in the columns V, VII, IX, and XI.

The said inadvertent error is hereby rectified and we now resubmit the correct Financial Results for the quarter ended June 30, 2022 which may kindly be taken on record and be uploaded on the Exchange website to disseminate the correct information to investors.

We regret the inconvenience caused.

Thanking you,

Yours faithfully,

For **GUJARAT THEMIS BIOSYN LIMITED**

Rahul Soni
Company Secretary & Compliance Officer



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter ended June 30, 2022

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Year Ended
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Income from operations	4,494.44	2,876.34	3,244.05	11,485.39
II	Other Income	142.25	150.90	113.29	405.01
III	Total Income (I+II)	4,636.69	3,027.24	3,357.35	11,890.40
IV	Expenditure				
	(a) Cost of raw material consumed	767.19	318.70	587.04	2,174.63
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock in Trade	318.33	304.13	33.03	(513.07)
	(d) Employee benefits expense	174.71	165.52	168.35	708.36
	(e) Finance Cost	6.24	17.87	19.56	82.78
	(f) Depreciation and Amortisation expenses	56.98	54.35	54.15	223.30
	(g) Other Expenses				
	i) Stores and spares	113.88	131.58	93.35	427.65
	ii) Power	430.12	270.97	386.75	1,489.85
	iii) Fuel	205.92	107.00	146.54	594.68
	iv) Water	27.38	17.72	24.10	88.33
	v) Other expenditure	179.05	252.76	132.52	710.44
	Total Expenses	2,279.80	1,640.60	1,645.39	5,986.95
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	2,356.89	1,386.64	1,711.96	5,903.45
VI	Exceptional items	-	-	-	-
VII	Profit (Loss) before Tax (V-VI)	2,356.89	1,386.64	1,711.96	5,903.45
VIII	Tax expenses				
	(a) Current Tax	599.12	401.57	423.88	1,533.80
	(b) Deferred Tax	(19.25)	6.19	(4.19)	7.24
IX	Net Profit (Loss) after tax (VII-VIII)	1,777.02	978.88	1,292.27	4,362.42
X	Other Comprehensive Income				
	(a) Items that will not be reclassified to Profit or Loss				
	(i) Remeasurement of defined benefit plans;	(2.70)	(7.68)	(1.04)	(10.79)
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	0.70	2.00	0.27	2.81
	(b) Items that will be reclassified to Profit or Loss				
	(i) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
XI	Total Comprehensive Income for the period (IX+X)	1,775.02	973.20	1,291.50	4,354.43
XII	Paid-up equity share capital	726.44	726.44	726.40	726.44
XIII	Other Equity	-	-	-	9,605.70
XIV	Earnings Per Share (Basic and Diluted)	12.23	6.74	8.89	30.03



Notes:

- 1 The financial results for the quarter ended June 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on July 27, 2022 .
- 2 Operating segments are reported in manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") of the Company . The CODM, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (CEO) of the Company. The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter June 30, 2022.
- 5 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been notified in the Gazette of India. However, the date from which it will be implemented has reportedly not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 6 The figures for the quarter ended March 31, 2022 represents the difference between audited figures in respect of the full financial year and the published figures of nine months ended December 31, 2021.
- 7 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

For GUJARAT THEMIS BIOSYN LIMITED



Dr. DINESH PATEL

Chairman

DIN : 00033273

Place: Mumbai

Date : July 27, 2022



Independent Auditor's Review report on quarterly unaudited financial results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review report to
The Board of Directors
GUJARAT THEMIS BIOSYN LIMITED


We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ("the Company") for the quarter ended June 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For GMJ & Co
Chartered Accountants
FRN: 103429W



CA Sanjeev Maheshwari
Partner

M. No.: 038755

UDIN: 22038755ANRO FX4003

Place : Mumbai

Date : July 27, 2021

